发明名称 PRO-DRUG FORM (P2PDOX) OF THE HIGHLY POTENT 2-PYRROLINODOXORUBICIN CONJUGATED TO ANTIBODIES FOR TARGETED THERAPY OF CANCER
摘要 Disclosed are methods, compositions and uses of conjugates of prodrug forms of 2-pyrrolinodoxorubicin (P2PDox) with antibodies or antigen-binding fragments thereof (ADCs), with targetable construct peptides or with other targeting molecules that are capable of delivering the P2PDox to a targeted cell, tissue or pathogen. Once delivered to the target cell, the ADC or peptide conjugate is internalized, a highly toxic 2-pyrrolinodoxorubicin (2-PDox) is released intracellularly. The P2PDox-peptide or ADC conjugates are of use to treat a wide variety of diseases, such as cancer, autoimmune disease or infectious disease.
申请公布号 US2017000896(A1) 申请公布日期 2017.01.05
申请号 US201615270542 申请日期 2016.09.20
申请人 Immunomedics, Inc. 发明人 Govindan Serengulam V.;McBride William J.;Sathyanarayan Nalini;Mazza-Ferreira Christine;Goldenberg David M.
分类号 A61K47/48;C07K16/10;C07K16/28;A61K45/06;C07K16/30 主分类号 A61K47/48
代理机构 代理人
主权项 1. A method of treating cancer comprising administering to a subject with cancer an antibody or antigen-binding antibody fragment that binds to a tumor-associated antigen (TAA), wherein the antibody or antigen-binding antibody fragment is conjugated to pro-2-pyrrolinodoxorubicin (P2PDox), wherein the antibody comprises human constant regions selected from the group consisting of IgG1, IgG2, IgG3 and IgG4.
地址 Morris Plains NJ US